Log In
BCIQ
Print this Print this
 

merestinib (LY2801653)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionC-Met inhibitor
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)
Mechanism of Actionc-Met receptor tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard Indication Cancer (unspecified)
Indication DetailsTreat advanced cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/29/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today